CAR T-cell therapy
A cancer treatment that redesigns a patient's own T-cells to attack cancer cells.
As defined in Derek Thompson
Where it comes up · 4
- Compounding For A Cure2 claims
- Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]2 claims
- Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]1 claim
- Derek Thompson1 claim
Most important claims · 6 of 6Search all claims for “CAR T-cell therapy” →
- CAR T-cell therapy requires extracting a patient's immune cells, flying them to a manufacturing site, gene-editing them, and flying them back within a short window because cell viability declines and the patients are gravely ill, which makes the process very hard to scale beyond niche use cases.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]
- GLP-1 drugs, initially synthesized from lizard venom to treat type 2 diabetes, turned out to reduce body-wide inflammation and rewire minds toward desired moderation (people wanting to eat more fruits and vegetables find it easier), and because many neurological issues like dementia and Alzheimer's may fundamentally be inflammation issues, we might have accidentally derived a partial medicine for Alzheimer's from the tongue of a lizard.Derek Thompson
- The 21st century will be marked by curing disease, as opposed to the prior century's small molecules and biologics that required repeated infusions to manage symptoms, because gene therapy, gene editing, and CAR T-cell therapy can correct disease at its molecular root in a single treatment.Compounding For A Cure
- CAR T-cell therapy has been very successful against leukemias, lymphomas, and myelomas, and Marrazzo expects it to be applied in the next 5 to 10 years to solid tumors that make up the other 93 percent of cancer, including lung, breast, and colon cancer.Compounding For A Cure
- Next-generation CAR T approaches, including in vivo methods such as those from Capstan, show potential to reduce tumors by 100 percent in more than 70 percent of patients and keep them controlled for long periods.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]
- Bristol Myers Squibb bought Celgene, a pioneer in CAR T-cell therapy, and has roughly the same number of employees delivering these compounds as the number of patients being treated, around 4,000 each.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]